Product analysis
Natural E-400 offers a simple, good-value way to supplement vitamin E in a clearly identified natural form. Its usefulness for cardiovascular support remains uncertain.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality100
Vitamin E is clearly identified in a natural form. That gives a firm basis for choosing it when the natural form matters to you.
Ingredient Transparency100
Both the vitamin E amount and form are stated. The straightforward label makes comparison with other vitamin E products easier.
Value For Money100
The natural-form vitamin E offers strong value at the serving cost. Price is a clear strength if vitamin E is the nutrient you need.
Customer Satisfaction93
Customer ratings are very positive across a large review base. That supports confidence in the satisfaction pattern without proving health benefits.
Product Focus30
The single-ingredient formula keeps its focus on vitamin E. A useful fit for cardiovascular support is not established.
- Format
Softgel - Container
- 250 Softgel(s)
- Per serving
- $0.10
- Customer rating
- 4.8 · 13,651 ratings
Goals
Natural E-400 declares 400 IU of vitamin E as D-alpha-tocopheryl acetate per serving, but that alone does not establish a useful fit for cardiovascular support. The product details provide no comparable milligram amount for marker studies, and the supplied results link it to no covered pathway or study-relevant dose.
How this product is rated for Cardiovascular Support
Ingredient fit56
Goal fit
Dose adequacy
Pathways0
Depth
Breadth
Evidence0
Evidence strength
Studied preparation
Formulation logic75
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Vitamin E (D-Alpha-Tocopheryl Acetate) | 400 IU |
How this ingredient is rated
Active Ingredient Quality & Bioavailability46
Natural (d-alpha) vs. Synthetic (dl-alpha)
Mixed Tocopherol Isomer Diversity
Tocotrienol Complex Inclusion
Dose, Safety & Label Transparency85
Therapeutic Dosage Range
Label Transparency and Isomer Specificity
Value100
Cost per Natural-Form Therapeutic Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Supplementation with vitamin E alone is associated with reduced myocardial infarction: a meta-analysis.
- Vitamin E ameliorates blood cholesterol level and alters gut microbiota composition: A randomized controlled trial.
- Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.
- Independent and combined associations of dietary antioxidant exposure with all-cause and cause-specific mortality in the general population.
- Tocotrienol rich fraction supplementation improved lipid profile and oxidative status in healthy older adults: A randomized controlled study.
- Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.
- Dietary n-3 Fatty Acid, α-Tocopherol, Zinc, vitamin D, vitamin C, and β-carotene are Associated with Age-Related Macular Degeneration in Japan.
- Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study.
- Long-term nutrient intake and 5-year change in nuclear lens opacities.
- Dietary intake of antioxidants and risk of age-related macular degeneration.
- Effects of delta-tocotrienol supplementation on Glycemic Control, oxidative stress, inflammatory biomarkers and miRNA expression in type 2 diabetes mellitus: A randomized control trial.
- Effect of vitamin E supplementation on serum C-reactive protein level: a meta-analysis of randomized controlled trials.
- Efficacy of Nutritional Interventions on Inflammatory Markers in Haemodialysis Patients: A Systematic Review and Limited Meta-Analysis.
- Vitamin E improves serum markers and histology in adults with metabolic dysfunction-associated steatotic liver disease: Systematic review and meta-analysis.
- Delta-tocotrienol supplementation improves biochemical markers of hepatocellular injury and steatosis in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial.